시장보고서
상품코드
1299825

세계의 펩티드 암 치료제 시장, 용량, 가격, 판매, 임상시험 동향(2029년)

Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029

발행일: | 리서치사: KuicK Research | 페이지 정보: 영문 600 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 펩티드 암 치료제 시장 규모는 150억 달러를 넘는 시장 기회를 가지고 있습니다.

세계의 펩티드 암 치료제 시장에 대해 조사했으며, 시장의 개요와 약제 동향, 임상시험 동향, 지역별 동향 및 시장에 참여하는 기업의 경쟁 구도 등을 제공하고 있습니다.

목차

제1장 펩티드 치료학의 서론

제2장 세계의 펩티드 암 치료제 시장 인사이트

  • 현재 시장 시나리오
  • 세계의 펩티드 암 치료제 시장 예측

제3장 세계의 펩티드 암 치료제 시장 동향, 지역별

  • 일본
  • 한국
  • 중국
  • 호주
  • 미국
  • 유럽

제4장 시판 암 펩티드약 인사이트 - 가용성, 비용, 용량, 적응 및 특허 인사이트

  • Firmagon(Degarelix)
  • Eligard(Leuprolide)
  • Lupron(Leuprolide Acetate)
  • Supprelin LA(Histrelin Acetate)
  • Gonax(Degarelix Acetate)
  • Trelstar(Triptorelin)
  • Decapeptyl SR(Treptorelin Acetate or Pamoate)
  • Velcade(Bortizomib)
  • Ninlaro(Ixazomib)
  • Kyprolis(Carfilzomib)
  • Istodax(Romidepsin)
  • Zoladex(Goserelin)
  • Cosmegen(Dactinomycin)
  • Somatuline Depot(Lanreotide)
  • Suprefact(Buserelin)
  • Sandostatin(Octreotide Acetate)
  • Bynfezia Pen(Octreotide)
  • Mepact(Mifamurtide)
  • Lutathera(Lutetium Lu 177 dotatate)
  • Netspot(Gallium Ga 68 dotatate)

제5장 출시 암 펩티드약 판매 인사이트(2019-2023년)

  • Lupron
  • Kyprolis
  • Zoladex
  • Lutathera
  • Sandostatin
  • Somatuline
  • Decapeptyl SR
  • Velcade
  • Ninlaro

제6장 세계의 펩티드 암치료 임상시험의 개요

  • 기업별
  • 국가별
  • 적응증별
  • 환자 부문별
  • 상별
  • 제제별

제7장 세계의 펩티드 암치료 임상시험 인사이트, 기업별, 국가별, 적응증별, 펩티드 부문별

  • 조사
  • 전임상
  • 제I상
  • 제I/II상
  • 제II상
  • 제II/III상
  • 제III상
  • 사전 등록
  • 등록

제8장 시판 암 펩티드 임상적 인사이트, 기업별, 국가별 및 적응증별

제9장 세계의 펩티드 암치료 시장 역학

제10장 치료용 펩티드의 표적

  • 신호전달 경로
  • 세포 주기 조절
  • 세포사 경로
  • 종양 억제 단백질
  • 전사 인자

제11장 펩티드 의약품과 기존 암 치료제의 비교

제12장 암치료에서 펩티드의 다양한 어프로치

제13장 펩티드 치료법의 응용과 암의 검출 조사 방법

  • 결장직장암
  • 폐암
  • 췌장암
  • 위암
  • 유방암
  • 전립선암

제14장 신생항원 백신 : 새로운 종양 면역치료

제15장 독 펩티드 : 암 펩티드 치료의 신시대

제16장 경쟁 구도

  • 3B Pharmaceuticals
  • AsclepiX Therapeutics
  • Bicycle Therapeutics
  • Biohaven Labs
  • BrightPath Biotherapeutics
  • Bristol-Myers Squibb
  • Edinburgh Molecular Imaging
  • FogPharma
  • GE Healthcare
  • Gnubiotics Sciences
  • Harvard University
  • Heidelberg Pharma AG
  • IDP Pharma
  • Janux Therapeutics
  • Medikine
  • Modulation Therapeutics
  • Novartis
  • PeptiDream
  • Pharm-Sintez
  • Roche
  • Sanofi
  • Sapience Therapeutics
  • Second Genome
  • Viewpoint Molecular Targeting
  • Vigeo Therapeutics
KSA 23.07.07

“Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029” Report Highlights:

  • Global Peptide Drug Market Opportunity: > USD 15 Billion
  • Marketed Cancer Peptides Drugs Sales Insight 2019 - 2023
  • Marketed Cancer Peptides Drugs Dosage, Patent& Price Insight
  • Marketed Cancer Peptides Drugs Clinical & Commercial Insight: 25 Drugs
  • Peptide Cancer Drug Clinical Trials Insight: > 200 Drugs
  • Global Peptide Cancer Drug Clinical Trials Insight By Company, Country Indication & Phase
  • Peptide Drug Development Proprietary Technologies By Company & Indication

Biologics have been an important class of drugs for several diseases including cancer. Till now, antibodies have dominated this domain of therapeutics but driven by new technological innovations, researchers have now shifted their new drug development approach towards peptides as preferred choice of anti-cancer agents. For a long time, peptides have been used as therapeutic agents; however, their potential in cancer has been a new area of interest. Due to their ability to offer advanced optimization strategies, peptide drugs have become an attractive area of research.

The development of peptide based drugs and therapies have made great progress in the last decade owing to several pharmaceutical companies developing novel proprietary technologies for producing innovative peptide therapeutics. For instance, South Korea's Nanotechnology and Integrated Bioengineering Centre (NBICE), pharmaceutical company has developed its own novel peptide therapeutic discovery and delivery technology platform called TOPscovery. The company has also created a subsequent clinical pipeline using this novel technology platform which is based on target oriented peptide therapeutic discovery and has target tissue / cell penetrating peptide delivery platform to delivery protein or antibody or siRNA into the target tissue such as that of the cancer cells.

This peptide discovery platform TOPscovery is focused on resolving fibrosis in liver, lung and heart and additionally, the platform technology to target tissue penetrating peptide carrier (NPEP - TPP) can be applied to protein, antibody having intracellular targets, this increase the efficacy and decreases the side effects to non - target. The development of proprietary platforms and novel technologies has been an increasingly important factor that is boosting innovation the today's development of peptide based anti-cancer therapies.

Moreover, the increasing number of companies collaborating and investing in the field is also a signification factor driving the growth of peptide therapeutics. A major reason of this has been the development of novel technologies. With more pharmaceutical companies and biotechs advancing their portfolio with innovative products developed from novel platforms, more companies gain interest in field which could ultimately lead to more collaboration or investment, increasing the overall competitive landscape of the merging global market of anti - cancer peptide therapies.

The trend of collaboration not only extends the research and development capabilities for both the companies but it also allows for assessing the investigational peptide product candidates and likely have an impact on global peptide therapeutic market in terms of increasing the pipeline of cancer peptides, advancements in discovery and optimization of products and the possibility of investigational several different combinational strategies.

For instance, in first quarter of 2023, PeptiDream announced a collaborative arrangement with Ono Pharmaceuticals to discover and develop novel macrocyclic constrained peptide-based drugs directed against targets chosen by Ono. Under the agreement, PeptiDream will apply its proprietary PDPS (Peptide Discovery Platform System) technology to identify and enhance macrocyclic constrained peptide drug candidates, while Ono will develop and commercialize the resulting peptide-based drugs globally under an exclusive license. PeptiDream will be eligible to receive an undisclosed upfront payment in addition to funding to carry out research, as well as added payments based on research, development and commercialization milestones based on global net sales.

In addition, the portfolio of novel cancer peptides with distinct characteristics expands as a result of the development of novel technologies and platforms by various pharmaceutical companies. This will provide diverse market opportunities for each and every therapeutic peptide product candidate. Furthermore, rise in the cancer prevalence and increasing research of the therapeutic use of cancer peptides is likely to be the key factors responsible for the growth of the market. Moreover, the increasing demand for effective and novel therapies can be further anticipated to bring more opportunities and growth in the market. Apart from this, awareness among healthcare professionals and patients about the significant adverse events associated with conventional cancer treatments will also lead to greater adoption towards peptide based therapeutics in cancer treatment.

Our report provides a comprehensive analysis about the current available anti-cancer peptide drugs and therapies while also providing information about their sales insight, patent information and their targeting cancer indication. Additionally, this report also includes the overall market perspective of peptides in different countries and provides a descriptive view on upcoming opportunities that might become available.

Table of Contents

1. Introduction to Peptide Therapeutics

  • 1.1 Overview of Peptide Therapeutics
  • 1.2 Classification Of Anticancer Peptides
  • 1.3 Significance of Peptides as Cancer Therapeutics

2. Global Cancer Peptide Therapeutics Market Insight

  • 2.1 Current Market Scenario
  • 2.2 Global Cancer Peptide Therapeutics Market Forecast

3. Global Peptide Cancer Therapeutics Market Trend By Region

  • 3.1 Japan
  • 3.2 South Korea
  • 3.3 China
  • 3.4 Australia
  • 3.5 US
  • 3.6 Europe

4. Marketed Cancer Peptides Drugs Insight - Availability, Cost, Dosage, Indication & Patent Insight

  • 4.1 Firmagon (Degarelix)
  • 4.2 Eligard (Leuprolide)
  • 4.3 Lupron (Leuprolide Acetate)
  • 4.4 Supprelin LA (Histrelin Acetate)
  • 4.5 Gonax (Degarelix Acetate)
  • 4.6 Trelstar (Triptorelin)
  • 4.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
  • 4.8 Velcade (Bortizomib)
  • 4.9 Ninlaro (Ixazomib)
  • 4.10 Kyprolis (Carfilzomib)
  • 4.11 Istodax (Romidepsin)
  • 4.12 Zoladex (Goserelin)
  • 4.13 Cosmegen (Dactinomycin)
  • 4.14 Somatuline Depot (Lanreotide)
  • 4.15 Suprefact (Buserelin)
  • 4.16 Sandostatin (Octreotide Acetate)
  • 4.17 Bynfezia Pen (Octreotide)
  • 4.18 Mepact (Mifamurtide)
  • 4.19 Lutathera (Lutetium Lu 177 dotatate)
  • 4.20 Netspot (Gallium Ga 68 dotatate)

5. Marketed Cancer Peptides Drugs Sales Insight (2019 -2023)

  • 5.1 Lupron
  • 5.2 Kyprolis
  • 5.3 Zoladex
  • 5.4 Lutathera
  • 5.5 Sandostatin
  • 5.6 Somatuline
  • 5.7 Decapeptyl SR
  • 5.8 Velcade
  • 5.9 Ninlaro

6. Global Peptide Cancer Therapeutics Clinical Trials Overview

  • 6.1 By Company
  • 6.2 By Country
  • 6.3 By Indication
  • 6.4 By Patient Segment
  • 6.5 By Phase
  • 6.6 By Drug Formulation

7. Global Peptide Cancer Therapeutics Clinical Trials Insight By Company, Country, Indication & Peptide Segment

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Phase-I
  • 7.4 Phase-I/II
  • 7.5 Phase-II
  • 7.6 Phase-II/III
  • 7.7 Phase-III
  • 7.8 Preregistration
  • 7.9 Registered

8. Marketed Cancer Peptides Clinical Insight by Company, Country & Indication

9. Global Peptide Cancer Therapy Market Dynamics

  • 9.1 Favorable Market Parameters
  • 9.2 Commercialization Challenges

10. Targets for Therapeutic Peptides

  • 10.1 Signal Transduction Pathways
  • 10.2 Cell Cycle Regulation
  • 10.3 Cell Death Pathways
  • 10.4 Tumor Suppressor Protein
  • 10.5 Transcription Factors

11. Peptide Drugs v/s Conventional Cancer Therapeutics

  • 11.1 Peptide v/s Chemotherapy
  • 11.2 Peptide v/s Monoclonal Antibody
  • 11.3 Peptide v/s Gene Therapy
  • 11.4 Peptide v/s Immunotherapy

12. Different Approaches of Peptides in Cancer Therapeutics

  • 12.1 Hormonal Peptides
  • 12.2 Peptide as Radionuclide Drug Carrier
  • 12.3 Peptide Vaccines
  • 12.4 Peptides as Cytotoxic Drug Carrier
  • 12.5 Anticancer Peptides
  • 12.6 Other Anticancer Drugs Closely Related to Peptides

13. Application of Peptides Therapeutics & Detection Methodology by Cancer

13.1 Colorectal Cancer

    • 13.1.1 Peptides in Treatment of Colorectal Cancer
    • 13.1.2 Proprietary Technologies

13.2 Lung Cancer

    • 13.2.1 Peptides in Treatment of Lung Cancer
    • 13.2.2 Proprietary Technologies

13.3 Pancreatic Cancer

    • 13.3.1 Peptide in Treatment of Pancreatic Cancer
    • 13.3.2 Proprietary Technologies
  • 13.4 Gastric Cancer
    • 13.4.1 Peptides in Treatment of Gastric Cancer
    • 13.4.2 Proprietary Technologies
  • 13.5 Breast Cancer
    • 13.5.1 Peptides in Treatment of Breast Cancer
    • 13.5.2 Proprietary Technologies
  • 13.6 Prostate Cancer
    • 13.6.1 Peptides in Treatment of Prostate Cancer
    • 13.6.2 Proprietary Technologies

14. Neoantigen Vaccine: An Emerging Tumor Immunotherapy

  • 14.1 Personalized Neoantigen Based Vaccine in Cancer
  • 14.2 Ongoing Clinical Advancements

15. Venom Peptides: New Era for Cancer Peptide Therapy

  • 15.1 Relevance of Venom Based Peptide Therapeutics
  • 15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides

16. Competitive Landscape

  • 16.1 3B Pharmaceuticals
  • 16.2 AsclepiX Therapeutics
  • 16.3 Bicycle Therapeutics
  • 16.4 Biohaven Labs
  • 16.5 BrightPath Biotherapeutics
  • 16.6 Bristol-Myers Squibb
  • 16.7 Edinburgh Molecular Imaging
  • 16.8 FogPharma
  • 16.9 GE Healthcare
  • 16.10 Gnubiotics Sciences
  • 16.11 Harvard University
  • 16.12 Heidelberg Pharma AG
  • 16.13 IDP Pharma
  • 16.14 Janux Therapeutics
  • 16.15 Medikine
  • 16.16 Modulation Therapeutics
  • 16.17 Novartis
  • 16.18 PeptiDream
  • 16.19 Pharm-Sintez
  • 16.20 Roche
  • 16.21 Sanofi
  • 16.22 Sapience Therapeutics
  • 16.23 Second Genome
  • 16.24 Viewpoint Molecular Targeting
  • 16.25 Vigeo Therapeutics
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제